JP2010534469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534469A5 JP2010534469A5 JP2010517493A JP2010517493A JP2010534469A5 JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5 JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- human
- kdr
- monoclonal
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95180507P | 2007-07-25 | 2007-07-25 | |
| PCT/GB2008/050615 WO2009013543A2 (en) | 2007-07-25 | 2008-07-23 | Targeted binging agents directed to kdr and uses thereof - 035 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534469A JP2010534469A (ja) | 2010-11-11 |
| JP2010534469A5 true JP2010534469A5 (enExample) | 2011-09-08 |
Family
ID=40281893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517493A Pending JP2010534469A (ja) | 2007-07-25 | 2008-07-23 | Ｋｄｒ指向性標的化結合物質およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8119130B2 (enExample) |
| EP (1) | EP2183028A2 (enExample) |
| JP (1) | JP2010534469A (enExample) |
| AU (1) | AU2008278803A1 (enExample) |
| CA (1) | CA2694396A1 (enExample) |
| WO (1) | WO2009013543A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119130B2 (en) | 2007-07-25 | 2012-02-21 | Medimmune Limited | Targeted binding agents directed to KDR and uses thereof—035 |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN104650229A (zh) * | 2011-11-02 | 2015-05-27 | 埃派斯进有限公司 | 抗-kdr抗体和使用方法 |
| US9441042B2 (en) | 2011-11-02 | 2016-09-13 | Apexigen, Inc. | Anti-KDR antibodies and methods of use |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| JP6225189B2 (ja) * | 2012-09-12 | 2017-11-01 | ニューリミューン ホールディング エイジー | ヒト膵島アミロイドポリペプチド（ｈＩＡＰＰ）特異的抗体およびその使用 |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| BR112017027702A2 (pt) * | 2015-06-30 | 2018-08-28 | Henlius Biotech Co Ltd | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2023010122A2 (en) | 2021-07-29 | 2023-02-02 | Sonoma Biotherapeutics, Inc. | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| PT1916001E (pt) * | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| US8119130B2 (en) | 2007-07-25 | 2012-02-21 | Medimmune Limited | Targeted binding agents directed to KDR and uses thereof—035 |
-
2008
- 2008-07-23 US US12/669,724 patent/US8119130B2/en not_active Expired - Fee Related
- 2008-07-23 WO PCT/GB2008/050615 patent/WO2009013543A2/en not_active Ceased
- 2008-07-23 EP EP08788590A patent/EP2183028A2/en not_active Withdrawn
- 2008-07-23 JP JP2010517493A patent/JP2010534469A/ja active Pending
- 2008-07-23 AU AU2008278803A patent/AU2008278803A1/en not_active Abandoned
- 2008-07-23 CA CA2694396A patent/CA2694396A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503189A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2019519199A5 (enExample) | ||
| JP2015227342A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| JP2015517300A5 (enExample) | ||
| JP2010506596A5 (enExample) | ||
| JP2017507657A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| JP2009531283A5 (enExample) | ||
| JP2021524275A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2011515073A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2010535032A5 (enExample) | ||
| JP2015212281A5 (enExample) | ||
| ME02607B (me) | Molekuli antitela koji imaju specifično vezivanje za humani il-13 | |
| JP2013523166A5 (enExample) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita |